Core--Molecular Laboratory

$iteman癌症中心的分子核心实验室（MCL）是一个共享资源设施，为基础研究和临床研究提供分子病理学服务。MCL的使命是迅速将基础研究观察结果转化为新的诊断和/或预后临床分子检测。MCL与研究人员合作开发和实施分子生物学分析，以分析人类恶性肿瘤中的突变和异常表达，MCL使用的方法范围从常规（基因组南方分析，PCR筛选，DNA测序）到项目特定技术（BAC探针，蛋白质截断测试，端粒长度）。新项目经常需要在项目特定的重点方法中调整和优化新的或现有的程序。研究者与MCL主任协商确定研究目标和分子模型。选择最适合项目的选项。这种个性化的关注和专业知识为癌症中心成员和其他华盛顿大学医学院的研究人员提供了大量的共享资源服务。随着对常见肿瘤遗传基础的理解的快速发展，专家研究支持临床研究的可用性将有助于加快遗传标记的评估，并迅速将研究成果转化为临床工具。MCL也是分子遗传学研究的关键设备资源，可供监督共享使用。分子测试的开发和费用由每个合作项目的研究者配置，并通过退款系统向MCL报销项目特定的试剂和服务。许多研究项目得到了

The Molecular Core Laboratory (MCL) of the $iteman Cancer Center is a shared resource facility that provides molecular pathology services to both basic research and clinical research studies. The mission of the MCL is to rapidly translate basic research observations to new diagnostic and/or prognostic clinical molecular tests. The MCL works with researchers to develop and implement molecular biology assays to analyze mutations and aberrant gone expression in human malignancies, The methods utilized in the MCL range from the routine (genomic Southern analysis, PCR screening, DNA sequencing) to project-specific techniques (BAC probes, protein truncation test, telomere length). New projects frequently require adaptation and optimization of new or existing procedures in a project-specific focused approach. The Investigators consult with the MCL director to define goals of the research and molecular tesl.ing options that best serve the project. This individualized attention and professional expertise affords a substantial economy of service from this shared resource to Cancer Center members and other Washington University School of Medicine researchers. With the rapid advancement of the understanding of the genetic basis of common neoplasias, the availability of expert research support for clinical studies will serve to expedite assessment of genetic markers and to rapidly translate research findings to clinical tools. The MCL is also a resource of key equipment for molecular genetic research available for supervised shared use. Molecular test development and fees are configured with the investigator per collaborative project with a chargeback system to reimburse the MCL for project-specific reagents and services. Many research projects supported by the MCL have resulted in translation of the findings to new clinical lab tests for patients at SCC and referred from other US centers. Test validation to clinical application is uniquely achieved through the interface with the personnel and facilities of the adjoining Clinical Molecular Diagnostic Laboratory facility [CAP & CLIA-certified], also directed by Barbara A. Zehnbauer, Ph.D.